Investigators report survival data for the bevacizumab biosimilar Byvasda with sintilimab (Tyvyt) in hepatitis B virus–associated advanced hepatocellular carcinoma (HCC).
Positive findings were reported for the bevacizumab biosimilar Byvasda in combination with the PD-1 inhibitor sintilimab (Tyvyt) for the first-line treatment of patients with advanced hepatocellular carcinoma (HCC).
Byvasda was developed by Innovent Biologics and sintilimab was developed by Innovent and Eli Lilly. A supplemental new drug application is under review with China’s National Medical Products Administration for the therapy combination.
The open-label ORIENT-32 study randomized patients 2:1 to the sintilimab-bevacizumab biosimilar combination (n = 380) or sorafenib (n = 191). Patients in the combination arm received intravenous sintilimab (200 mg every 3 weeks) plus intravenous bevacizumab biosimilar (15 mg/kg every 3 weeks). The sorafenib dosage was 400 mg orally twice daily.
At a median follow-up of 10 months, the independent radiological review committee–assessed median progression-free survival (PFS) was 4.6 months (95% CI, 4.1-5.7) for patients in the combination arm vs 2.8 months (95% CI, 2.7-3.2) for the sorafenib group (HR, 0.56; 95% CI, 0.46-0.70; P < .0001).
Median overall survival (OS) was significantly longer for patients in the combination arm vs the sorafenib group: median not reached (95% CI, not reached-not reached) vs 10.4 months (95% CI, 8.5-not reached; HR 0.57, 95% CI, 0.43-0.75; P < .0001).
Investigators said the most common grade 3/4 treatment related adverse events (TRAEs) were hypertension (14% of the sintilimab-bevacizumab biosimilar group vs 6% of the sorafenib group) and palmar-plantar erythrodysaesthesia syndrome (none vs 12%, respectively).
Serious adverse events were noted in 32% of patients in the combination arm vs 19% of patients in the sorafenib group. TRAEs leading to death occurred in 6 (2%) and 2 (1%) patients in the combination vs sorafenib groups, respectively.
“Sintilimab in combination with bevacizumab biosimilar [Byvasda] showed significant improvements in OS and PFS compared with sorafenib in the first-line treatment of Chinese patients with unresectable, hepatitis B virus [HBV]-associated HCC, with no new safety signals,” the investigators said.
In the safety and activity lead-in portion of the trial (n = 24), ≥ grade 3 TRAEs occurred in 7 (29%) patients.
"ORIENT-32 is the first large-scale study to show the benefit of first-line treatment in HBV-associated HCC with combination immunotherapy,” said lead author Fan Jia, MD, of Zhongshan Hospital of Fudan University, Shanghai, China.
Byvasda was approved in China in June 2020. Sintilimab is approved in China and a biologics license application for the agent was accepted for review by the FDA in May 2021.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.